🩺 ALB-TRIAL wrap-up, #biomarkers, #POC biosensors & key decisions on data, #IP + exploitation 👩🔬
🫶 A heartfelt thank you to SEAB member Prof. Tilman Sauerbruch for his unwavering support throughout the years!
#cirrhosis #ACLF
@medblab.bsky.social
🩺 ALB-TRIAL wrap-up, #biomarkers, #POC biosensors & key decisions on data, #IP + exploitation 👩🔬
🫶 A heartfelt thank you to SEAB member Prof. Tilman Sauerbruch for his unwavering support throughout the years!
#cirrhosis #ACLF
@medblab.bsky.social
Marko Korenjak took us on a lively 7-year-long journey, while Minneke Coenraad & Robert Schierwagen highlighted the Delphi consensus, patient communication & the project's legacy. 🚀
#Hepatology #Horizon2020
@europeliver.bsky.social
Marko Korenjak took us on a lively 7-year-long journey, while Minneke Coenraad & Robert Schierwagen highlighted the Delphi consensus, patient communication & the project's legacy. 🚀
#Hepatology #Horizon2020
@europeliver.bsky.social
🥳 Jonel Trebicka opened #MICROB-PREDICT's Final GA Meeting today, looking back on 7 years of research, 100+ publications & major achievements.
Now it’s time for the final push! 🔬👏
#ACLF #cirrhosis #microbiome
@medblab.bsky.social
🥳 Jonel Trebicka opened #MICROB-PREDICT's Final GA Meeting today, looking back on 7 years of research, 100+ publications & major achievements.
Now it’s time for the final push! 🔬👏
#ACLF #cirrhosis #microbiome
@medblab.bsky.social
Jonel Trebicka & Nikolaj Torp are joined by investigators and consortium partners to evaluate progress and coordinate next steps for our interventional study targeting acute decompensation in cirrhosis. @medblab.bsky.social
Jonel Trebicka & Nikolaj Torp are joined by investigators and consortium partners to evaluate progress and coordinate next steps for our interventional study targeting acute decompensation in cirrhosis. @medblab.bsky.social
👉 Novel therapeutics & challenges in managing #MASLD (Metabolic dysfunction–associated steatotic liver disease)
👉 Novel therapeutics & challenges in managing #MASLD (Metabolic dysfunction–associated steatotic liver disease)
🥳 Partners will reflect on results, the ALB-TRIAL, biomarkers, publications, the project's legacy and exploitation.
🎤 Wednesday's Masterclass will start with a Science Slam!
#Microbiome #LiverHealth
🥳 Partners will reflect on results, the ALB-TRIAL, biomarkers, publications, the project's legacy and exploitation.
🎤 Wednesday's Masterclass will start with a Science Slam!
#Microbiome #LiverHealth
@decision4liver.bsky.social
@easlnews.bsky.social
@decision4liver.bsky.social
@easlnews.bsky.social